Australia Anemia Drugs Market Report 2022 to 2030

Australia Anemia Drugs Market Analysis

$ 3999

Australia's Anemia drugs market was valued at $192 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.4% from 2022 to 2030 and will reach $423 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and awareness among people in Australia. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Roche, Sanofi, Novartis, Merck, Novo Nordisk, Otsuka, and Baxter among others.

ID: IN10AUPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Nandini Shah

Buy Now

Australia Anemia Drugs Market Executive Summary

Australia's Anemia drugs market was valued at $192 Mn in 2022 and is estimated to expand at a CAGR of 10.4% from 2022-30 and will reach $423 Mn in 2030. Australia is a nation with a population of approximately 25.7 million people.1 It is a generally healthy nation, with life expectancies in the top 10 of OECD nations. Anaemia is a condition in which the number of red blood cells or the concentration of hemoglobin in them is lower than usual. Haemoglobin is required to carry oxygen, and if you have too few or malformed red blood cells, or not enough hemoglobin, your blood's capacity to carry oxygen to the body's tissues will be reduced. Symptoms include weariness, weakness, dizziness, and shortness of breath, among others.

In Australia, the prevalence of anemia in children under the age of five years is approximately 8%, equal to over 100,000 children whereas in pregnant women it was 16% in 2019 (WHO). The most prevalent cause of anemia in children is iron deficiency.

Market Dynamics

Market Growth Drivers

Anemia is a common condition in Australia, with a significant proportion of the population suffering from iron deficiency anemia, anemia of chronic disease, or anemia caused by other medical conditions. As the population ages, the prevalence of anemia is expected to increase, driving demand for anemia drugs. Anemia can have a substantial impact on a patient's quality of life, and there is a rising demand for more effective treatments that can relieve symptoms and enhance patients' overall well-being. This is pushing the development of novel anemia medications, such as ESAs, which boost red blood cell formation. The general public is becoming more aware of anemia and its causes, which is prompting more people to seek medical attention for their disease. This raises the demand for anemia medications, notably iron supplements. In recent years, the Australian government has made major investments in healthcare, with a special emphasis on expanding access to vital drugs. This contributes to the expansion of the anemia drug industry by making these medications more inexpensive.

Market Restraints

In Australia, the anemia drugs industry is highly competitive, with several major pharmaceutical companies and local players contending for market dominance. This makes it difficult for new entrants to establish a presence in the market and puts pressure on current businesses to differentiate their products and maintain competitive pricing. The Australian government is dedicated to making medications inexpensive and available to all Australians, and it has implemented a number of cost-control initiatives. This includes a pricing mechanism that relates drug prices to therapeutic value, putting pressure on drug producers to keep prices low. Anemia medications can have serious negative effects, especially if they are not used correctly or if patients have pre-existing medical issues. This can lead to safety concerns, which can harm medication producers' reputations and limit the market for their goods.

Competitive Landscape

Key Players

Pfizer
Roche
Sanofi
Novartis
Merck
Novo Nordisk
Otsuka
Baxter
Sun Pharmaceuticals

Notable Deals

December 2021: CSL, an Australian biopharma, has acquired Vifor Pharma for $11.7 Bn, a specialist pharmaceutical business with leadership in iron deficiency, nephrology, and cardio-renal therapy.

Healthcare Policies and Regulatory Landscape

The Therapeutic Goods Administration (TGA) is responsible for the quality, safety, efficacy, and timely availability of pharmaceuticals and medical equipment in Australia under the Therapeutic Goods Act 19891 and the Therapeutic Goods Regulations 2. The TGA's public image is that it evaluates prescription drugs, yet this is only one of several TGA functions. Non-prescription medications, medical devices, and vitamin, nutritional, and herbal items are also regulated by the TGA. The Australian Register of Therapeutic Goods (ARTG) has roughly 48 000 goods. This figure comprises around 21 000 devices and 27 000 medications, only 3500 of which are registered prescription-only goods.

Reimbursement Scenario

The government-funded Pharmaceutical Benefits Scheme (PBS) in Australia delivers most medications at little or no cost to Australians. Increasing budget constraints, as well as expectations for access to quality, affordable healthcare and new therapeutic developments, are putting an emphasis on PBS's sustainability and cost-effectiveness. The great majority of Australians are entitled to medicines subsidized by the Australian government under PBS. The PBS is a supplement to Medicare, which is a government-funded and operated system that provides free or subsidized medical and hospital services.

Iron supplements, which are the most commonly prescribed drugs for anemia in Australia, are usually available over the counter and are not reimbursed under the PBS. However, there are some exceptions, such as when the patient has a medical condition that causes malabsorption of iron or if they are unable to tolerate oral iron supplements.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Bn)

Iron Deficiency
CKD (Chronic Kidney Disease)
Sickle Cell
Aplastic
Others

By Drugs

Dietary Supplements
Medicines

The types of nutritional supplements are further broken down into iron and vitamin supplements, among other categories, whilst the categories of medicines include antibiotics, hormones (erythropoietin), and chelation therapy (lead poisoning), among others.

By Distribution Channel (Revenue, USD Bn)

Hospital Pharmacy
Store Pharmacy
Online
Others

The distribution channel for anemia drugs in Australia is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.